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Although proinflammatory cytokines such as TNF are critical for containment of tuberculosis,
they can also exacerbate disease when produced at high levels. In this issue of Cell, Roca and
Ramakrishnan demonstrate that high TNF production induces reactive oxygen species in infected
macrophages, ultimately leading to macrophage necrosis and bacterial dissemination.One-third of the human population is esti-
mated to be infected withMycobacterium
tuberculosis; however, of those individ-
uals, only 5% to 10% will develop active
tuberculosis (TB) at some point during
their lives. Historically, progression of
latent to active TB infection has been
attributed to a weakening of the immune
system, resulting in an inability to control
bacterial replication. This is perhaps best
illustrated by humans coinfected with
HIV, who are approximately 25 times
more likely to develop TB disease
compared to humans without HIV. How-
ever, it is becoming increasingly clear
that the opposite might also be true and
that in some cases TB susceptibility can
be attributed to overactivity of the im-
mune system. In this issue of Cell, Roca
and Ramakrishnan (2013) illustrate how
a critical mediator of the inflammatory
response to TB, tumor necrosis factor
(TNF), can increase both resistance and
susceptibility to infection via the produc-
tion of reactive oxygen species (ROS).
In their previous work, the Ramak-
rishnan laboratory identified a critical
role for the enzyme leukotriene A4 hydro-
lase (LTA4H) in determining the sus-
ceptibility of zebrafish to infection with
Mycobacterium marinum, a close relative
of M. tuberculosis (Tobin et al., 2012).
LTA4H is responsible for the production
of the proinflammatory lipid leukotriene
B4 (LTB4), which can directly induce the
transcription of TNF. In infected zebrafish
with high LTA4H activity, increased TNF
production was initially associated with
reduced bacterial growth inside macro-
phages. However, this early growth
restriction was rapidly followed bymacro-
phage necrosis, which enabled bacterialreplication in the permissive extracellular
environment and resulted in higher overall
bacterial burdens. In humans, differential
LTA4H activity has also been implicated
in the severity of TB infection, particularly
in patients suffering from TB meningitis
(Tobin et al., 2012). It was found that indi-
viduals homozygous for high LTA4H
expression alleles had a significantly
reduced survival compared to heterozy-
gotes, strengthening the notion that high
levels of inflammation can worsen the
outcome of TB infection.
How can this increased susceptibility of
TB meningitis patients with a proinflam-
matory LTA4H genotype be explained?
Using their zebrafish model, Roca and
Ramakrishnan set out to identify the
source of macrophage death under
LTA4H-high conditions. Because TNF is
known to be a potent inducer of mito-
chondrial ROS production, they incu-
bated zebrafish embryos with several
ROS scavengers and found that this
reversed the susceptibility of LTA4H-
high animals (Roca and Ramakrishnan,
2013). These data suggested that exces-
sive inflammation could be a driving
factor for ROS production during myco-
bacterial infection. To test this further,
the authors injected recombinant TNF,
thereby mimicking the LTA4H-high state.
Initially, this led to a reduction in bacterial
growth, indicating that TNF-induced ROS
can mediate antimicrobial activity inside
macrophages. However, at later times
this phenotype was reversed, at which
point high TNF levels were associated
with increased macrophage death and
extracellular bacterial growth. It is inter-
esting to point out that high TNF levels
only increased ROS production in in-Cellfected macrophages, raising the possibil-
ity that mycobacteria actively contribute
to and perhaps benefit from this process.
It has been observed previously that
mycobacteria are capable of escaping
from the phagosome into the cytosol by
secreting the virulence factor ESAT6, a
process that is rapidly followed by host
cell necrosis (Simeone et al., 2012; van
der Wel et al., 2007). It will be interesting
to explore whether macrophage ROS
production is involved in this escape-
associated necrosis and, if so, to what
extent mycobacterial factors are actively
contributing to this.
Given that TNF-mediated ROS produc-
tion can have both beneficial and detri-
mental effects for the host, could this be
exploited to develop more effective
antituberculosis therapies? Using gene-
specific knockdown, Roca and Ramak-
rishnan identified that the macrophage
death under high TNF conditions involved
the kinases RIP1 and RIP3, indicating that
the cells die via programmed necrosis
or necroptosis. Following the induction
of ROS, cells can undergo necroptosis
via two distinct pathways. One involves
the mitochondrial matrix protein cyclophi-
lin D and the other the lipid ceramide.
Knockdown of either the cyclophilin D or
the ceramide pathway under high TNF
conditions resulted in reduced bacterial
burdens, while largely preventing macro-
phage necroptosis. Furthermore, com-
bined inactivation of both pathways
rendered the macrophages hyperresist-
ant to infection, an effect that was
mimicked by the orally available inhibitors
alisporivir and desipramine that target
the cyclophilin D and ceramide pathways,
respectively. These findings illustrate that153, April 25, 2013 ª2013 Elsevier Inc. 507
Figure 1. Increasing TB Treatment Efficacy Using Host-Specific Therapies
In individuals with an LTA4H-high genotype, mycobacterial infection is initially controlled by TNF-medi-
ated ROS production. If infected individuals are left untreated, consistently high ROS production can lead
to macrophage necroptosis, resulting in release of bacteria into the permissive extracellular environment
and bacterial dissemination (left). However, if these individuals are treated using specific genotype-
directed drugs such as alisporivir and desipramine, macrophage necroptosis can be blocked while ROS-
mediated antimicrobial activity can be maintained, thereby resulting in intracellular bacterial containment
and a lower overall bacterial burden (right).TNF-mediated ROS production functions
as a double-edged sword; it lowers the
number of bacteria per macrophage, but
it also induces macrophage necroptosis,
leading to enhanced extracellular bacte-
rial replication. However, by using specific
necroptosis inhibitors, it might be
possible to devise novel antituberculosis
therapies that preserve ROS-dependent
antimicrobial activity without facilitating
bacterial dissemination (Figure 1). Such
specific therapies could substantially
benefit people with LTA4H-high geno-
types, whereas they presumably wouldn’t
affect those with an LTA4H-low genotype.
This contrasts to more general anti-
inflammatory therapies like glucocorti-
coids, which might harm individuals that508 Cell 153, April 25, 2013 ª2013 Elsevier Insuffer from TB disease as a result of low
inflammation.
What other factors might contribute to
the increased TB susceptibility of humans
with an LTA4H-high genotype? Next
to inducing TNF transcription, LTB4
also functions as a chemoattractant for
granulocytes, macrophages, and effector
T cells (Serhan and Prescott, 2000; Tager
et al., 2003). These recruited cells could
contribute substantially to the overall
inflammation in humans with an LTA4H-
high genotype, in part via the overpro-
duction of TNF. Given that high TNF levels
can have detrimental effects on TB
susceptibility, this raises an important
question regarding vaccine design
because most vaccine candidates arec.screened for the capacity to induce multi-
functional T cells capable of producing
cytokines such as TNF (Derrick et al.,
2011; Seder et al., 2008). Although multi-
functional T cells might be associated
with the highest degree of protection, it
is not clear whether the tested cytokines
like TNF are actually involved in this. In
fact, TNF appears dispensable for the
protection of Th1 cells against TB, at least
in mice (Gallegos et al., 2011). Further-
more, in settings of necrotic granulomas,
TNF blockade can actually enhance
bacterial clearance (Skerry et al., 2012).
Therefore, these findings together with
the new data by Roca and Ramakrishnan
make a strong case that vaccine develop-
ment should not just focus on inducing
inflammation but rather on inducing the
right type of inflammation. If successful,
the combination of such vaccines with
genotype-directed drug therapies prom-
ises to bring us one step closer toward
eliminating TB in the coming decades.
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